Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Grand View Research | PRODUCT CODE: 1571766

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1571766

Human Embryonic Stem Cells Market Size, Share & Trends Analysis Report By Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), By Region, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

Human Embryonic Stem Cells Market Growth & Trends:

The global human embryonic stem cells market size is expected to reach USD 4.08 billion by 2030, registering to grow at a CAGR of 10.5% from 2024 to 2030 according to a new report by Grand View Research, Inc. Application of hESCs as a promising donor source for cellular transplantation therapies is anticipated to bolster progress through to 2025. hESCs technology tends to be useful for tissue engineering in humans due to high histocompatibility between host and graft.

Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.

In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.

Furthermore, hESCs can be easily differentiated into defined neurons, neural lineages, oligodendrocytes, and astrocytes. Aforementioned characteristic makes it useful in studying the sequence of events that take place during early neurodevelopment.

However, use of stem cells derived from viable embryos is fraught with ethical issues, prompting scientists to explore other methods to generate ESCs. The other methods include derivation of embryonic germ cells, stem cells from dead embryos, and other techniques.

Human Embryonic Stem Cells Market Report Highlights:

  • Regenerative medicines dominated the market with a share of 61.1% in 2023. Regenerative medicines offer significant advancements in treating several diseases. Moreover, pluripotent cells originating from human embryos have been central to biomedical research.
  • The stem cell biology research segment is expected to witness the fastest CAGR of 11.4% over the forecast period. Several biopharmaceutical companies have explored the potency of stem cell biology in the past.
  • North America human embryonic stem cells dominated the market in 2023 owing to robust research infrastructure institutions and facilities. The rise in chronic diseases and genetic disorders has created a huge demand for gene therapies.
  • Asia Pacific human embryonic stem cell market is anticipated to witness significant growth in the forecast period.
Show more
Product Code: GVR-1-68038-394-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Human Embryonic Stem Cells Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Human Embryonic Stem Cells Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. Human Embryonic Stem Cells Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Human Embryonic Stem Cells Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Regenerative Medicine
    • 4.3.1. Regenerative Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Stem Cell Biology Research
    • 4.4.1. Stem Cell Biology Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tissue Engineering
    • 4.5.1. Tissue Engineering Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Toxicology Testing
    • 4.6.1. Toxicology Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Human Embryonic Stem Cells Market: Regional Estimates & Trend Analysis

  • 5.1. Human Embryonic Stem Cells Market Share, By Region, 2023 & 2030 (USD Million)
  • 5.2. North America
    • 5.2.1. North America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. U.S. Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Canada Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.4. Mexico
      • 5.2.4.1. Mexico Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. UK Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Germany Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. France Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Italy Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Spain Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.7. Denmark
      • 5.3.7.1. Denmark Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Sweden Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Norway Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. China
      • 5.4.2.1. China Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Japan Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. India Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.5. South Korea
      • 5.4.5.1. South Korea Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Australia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Brazil Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Middle East and Africa
    • 5.6.1. Middle East and Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Saudi Arabia
      • 5.6.2.1. Saudi Arabia Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. UAE
      • 5.6.3.1. UAE Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. South Africa
      • 5.6.4.1. South Africa Human Embryonic Stem Cells Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis by Key Market Participants
  • 6.2. Company Categorization
  • 6.3. Company Heat Map Analysis
  • 6.4. Company Profiles
    • 6.4.1. Thermo Fisher Scientific, Inc.
      • 6.4.1.1. Participant's Overview
      • 6.4.1.2. Financial Performance
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Recent Developments/ Strategic Initiatives
    • 6.4.2. STEMCELL Technologies
      • 6.4.2.1. Participant's Overview
      • 6.4.2.2. Financial Performance
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Recent Developments/ Strategic Initiatives
    • 6.4.3. Merck KGaA
      • 6.4.3.1. Participant's Overview
      • 6.4.3.2. Financial Performance
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Recent Developments/ Strategic Initiatives
    • 6.4.4. CellGenix GmbH
      • 6.4.4.1. Participant's Overview
      • 6.4.4.2. Financial Performance
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Recent Developments/ Strategic Initiatives
    • 6.4.5. PromoCell GmbH
      • 6.4.5.1. Participant's Overview
      • 6.4.5.2. Financial Performance
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Recent Developments/ Strategic Initiatives
    • 6.4.6. Takara Bio
      • 6.4.6.1. Participant's Overview
      • 6.4.6.2. Financial Performance
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Recent Developments/ Strategic Initiatives
    • 6.4.7. Lonza
      • 6.4.7.1. Participant's Overview
      • 6.4.7.2. Financial Performance
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Recent Developments/ Strategic Initiatives
    • 6.4.8. Cellartis AB
      • 6.4.8.1. Participant's Overview
      • 6.4.8.2. Financial Performance
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Recent Developments/ Strategic Initiatives
    • 6.4.9. ATCC
      • 6.4.9.1. Participant's Overview
      • 6.4.9.2. Financial Performance
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Recent Developments/ Strategic Initiatives
    • 6.4.10. AcceGen
      • 6.4.10.1. Participant's Overview
      • 6.4.10.2. Financial Performance
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Recent Developments/ Strategic Initiatives
    • 6.4.11. Cell Applications, Inc.
      • 6.4.11.1. Participant's Overview
      • 6.4.11.2. Financial Performance
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Recent Developments/ Strategic Initiatives
    • 6.4.12. Bio-Techne
      • 6.4.12.1. Participant's Overview
      • 6.4.12.2. Financial Performance
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Recent Developments/ Strategic Initiatives
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!